Outline of Efficacy Study
Hepatitis C

Hepatitis C - In Vivo Outline of Efficacy Study

The humanized liver mouse model has been utilized commercially for over 15 years and more than 150 Hepatitis C (HCV) leads have been evaluated. The model now serves as the gold standard in HCV efficacy testing, and the predictive value of the uPA/SCID chimeric mouse has been confirmed by multiple clinical trial results. 

Sample of key steps:

Step 1: Tolerability / Pharmacokinetic analysis 
Step 2: Efficacy study 
Step 3: Dose response analysis 
Step 4: Combination therapy study

Standard measurements:

human serum albumin (hAlb) 

Hepatitis C

Approximately 200 million people worldwide suffer with Hepatitis C and risk development of fibrosis, cirrhosis, liver failure and cancer. Half do not respond to current therapy and face liver transplant or death.

Hepatitis C only infects humans or chimpanzees, so finding a test subject for the development of therapies and vaccines is extremely difficult, time constraining and with the chimpanzee model, very expensive.

PXB-Mouse® platform technology is a cost effective animal model that contributes important advantages to research on Hepatitis C and other liver related diseases.